mandag den 6. februar 2017

Week 6-2017 Novo B purchased at a price: 232.18

Dear reader.
 
I see Novo as a good opportunity for a capital gain in the long term, I am sure that Novo will reach a price at 270
 
In the short term we will see:
 
· Lower price in the United States due. Trump· An action in the United States, where companies are alleged to have coordinated the prices of insulin· Back purchases and dividends· New Managing. Director of Novo Nordisk Lars Fruergaard Jørgensen.
 
So the outlook for 2017 is downgraded, as now seen risk of a decline in revenue and earnings in local currency due. to USA, but maybe Novo can win a little on the Danish currencyNovo Nordisk will in the coming year to buy back own shares totaling 16 billion. kr. It is an extension of the previous program, which was for 15 billion. kr. in 2016. In addition to the payment of dividends.


 
In the long run we will see this:
 
Opens for major acquisitions or more research and developmentNew products on the marketNovo is well equipped for the future (has money in the bank)
 

Novo Nordisk is gets ready to seriously bring billions into play in the quest for growth, this may be an acquisition or more research and development

Novo is currently working. get one or more product on the market for obesity.

 At Novo´s home page you can read this:

Novo Nordisk increased adjusted operating profit by 6% in local currencies in 2016
Sales increased by 6% in local currencies and by 4% in Danish kroner to DKK 111.8 billion.
Sales of Tresiba® increased by 221% to DKK 4.1 billion (219% in Danish kroner).
Sales of Victoza® increased by 12% to DKK 20.0 billion (11% in Danish kroner).
Sales of Saxenda® increased by 245% to DKK 1.6 billion (243% in Danish kroner).  
Sales in the USA increased by 4% (4% in Danish kroner).
Sales in International Operations increased by 14% (2% in Danish kroner).
Sales in Region China increased by 12% (6% in Danish kroner).
Operating profit was unchanged in local currencies and decreased by 2% in Danish kroner to DKK 48.4 billion. Adjusted for the non-recurring income related to the partial divestment of NNIT and the income related to out-licensing of assets for inflammatory disorders, both in 2015, operating profit in local currencies increased by 6%, in line with the most recent guidance of a '5-7% growth in local currencies' provided in October 2016.
Net profit increased by 9% to DKK 37.9 billion. Diluted earnings per share increased by 11% to DKK 14.96. Adjusted for the partial divestment of NNIT, net profit and diluted earnings per share increased by 17% and 19%, respectively.
In November 2016, Novo Nordisk announced that Tresiba® demonstrated a safe cardiovascular profile and a statistically significant 40% reduced risk of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial.
Also in November 2016, Novo Nordisk received the FDA approval of Xultophy® 100/3.6, the once-daily combination of insulin degludec (Tresiba®) and liraglutide (Victoza®). In January 2017, Novo Nordisk received EU approval of Fiasp®, the new-generation fast-acting insulin.
On 1 January 2017, Lars Fruergaard Jørgensen replaced Lars Rebien Sørensen as president and CEO, who retired after 34 years of loyal service with the company, the last 16 years as CEO.  
For 2017, reported sales growth is expected to be 1-6% measured in Danish kroner, positively impacted by currencies of 2 percentage points. Reported operating profit growth is expected to be 0-5% measured in Danish kroner, positively impacted by currencies of 2 percentage points.  
At the Annual General Meeting on 23 March 2017, the Board of Directors will propose a final dividend of DKK 4.60 for 2016 per share of DKK 0.20. The expected total dividend for 2016 of DKK 7.60 per share, of which DKK 3.00 per share was paid as interim dividend in August 2016, corresponds to an increase of 19% compared to 2015. The Board of Directors furthermore intends to initiate a new 12-months share repurchase programme of up to DKK 16 billion.  

Lars Fruergaard Jørgensen, president and CEO: "2016 was a challenging year. While we met our financial guidance for the year, strong market headwinds in the USA meant that we had to revise our long-term financial targets. However, 2016 was also a year in which we announced very encouraging clinical data for our key products, providing a solid foundation for future growth."


Therefore, I am sure that Novo B is the right choice, we would certainly see a price 270 within 2-3 years.Novo is well equipped for the future
 
Recommendation:2017 Buy / Hold2018 Hold / Hold

See you soon

Ingen kommentarer:

Tilføj en kommentar